RECRUITING

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.

Official Title

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

Quick Facts

Study Start:2025-04-15
Study Completion:2027-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06665945

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Women aged 21 years or older
  2. 2. Diagnosed with any stage or type of ovarian cancer within the last 8 weeks
  1. 1. Any other active malignancy
  2. 2. Other diagnosis of any cancer within the last 6 months
  3. 3. Treatment for any cancer within the last 6 months
  4. 4. History of ovarian cancer at any time
  5. 5. Currently receiving chemotherapy for ovarian cancer
  6. 6. Has already undergone complete ovarian mass resection
  7. 7. Unable to provide blood sample

Contacts and Locations

Study Contact

Sophie Eckel, CCRC, MPH, CPH
CONTACT
801 585 9823
sophie.eckel@utah.edu

Principal Investigator

Theresa Werner, MD
PRINCIPAL_INVESTIGATOR
Huntsman Cancer Institute/ University of Utah

Study Locations (Sites)

Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States

Collaborators and Investigators

Sponsor: University of Utah

  • Theresa Werner, MD, PRINCIPAL_INVESTIGATOR, Huntsman Cancer Institute/ University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-15
Study Completion Date2027-12-01

Study Record Updates

Study Start Date2025-04-15
Study Completion Date2027-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Ovarian Cancer